Topics: | Anemia of CKD | SGLT2 Inhibitors & CKD | Executive Order on Advancing Kidney Health

Advent of the HIF Stablizers: Key Considerations for Anemia of CKD Care


Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of drugs in late-stage trials that may soon shift the balance of treatment for anemia of chronic kidney disease (CKD). These oral agents are well-tolerated by patients, unlike red-cell transfusions and conventional erythropoiesis-stimulating agents (ESAs). In addition, HIF-PHIs, unlike ESAs, are able to increase hemoglobin (Hgb) levels irrespective of iron supplementation or inflammatory status.

In light of the potential of these groundbreaking emerging therapies, it is critical that nephrology clinicians are aware of HIF-PHIs and their safety and efficacy data. This educational activity, “Advent of the HIF-PHIs: Key Considerations for Anemia of CKD Care,” will help participants evaluate the risks and benefits of conventional anemia of CKD treatments, as well as the latest evidence and potential roles of the HIF-PHIs, so that, upon approval, they can be properly incorporated into patient care.

Learning Objectives

This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

  • Evaluate the risks and benefits of ESAs, iron, and blood transfusions in anemia of CKD care
  • Assess the most up-to-date evidence and potential roles of the HIF-PHIs in clinical development for the management of anemia of CKD

Target Audience

This activity is intended for nephrologists and nurse practitioners who diagnose and manage patients with or at risk of CKD.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CME Credit Designation

Boston University School of Medicine designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Designation Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through BUSM’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

MIPS Credit Designation Statement

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

Nursing Credit Designation

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, Boston University School of Medicine, and Rockpointe. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses to be determined.

Steering Committee

Jay Wish, MD

Bruce Spinowitz, MD


These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. Trustees of Boston University makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will trustees of Boston University be liable to anyone for any decision made or action take in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.


This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Disclosures will be made known to participants prior to the activity.

Special Services

Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.).  Please email at least 5 days prior to the program.


Jointly provided by the Boston University School of Medicine, Postgraduate Institute for Medicine, and Rockpointe



Supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.


Dallas/Fort Worth Program Faculty


Atlanta Program Faculty


Chicago Program Faculty